Drug intelligence / Profile preview

ADGN-F8

Development stage: Preclinical
Lead developer: Aanastra
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

ADGN-F8 is a biologic therapeutic candidate developed by Aanastra Inc. for the treatment of bleeding disorders, including hemophilia A. It functions as a Factor VIII (F8) stimulant, aiming to enhance the coagulation pathway in patients with congenital or acquired hemic and lymphatic conditions. Currently in the preclinical development stage, the drug is designed to address deficiencies in coagulation factor VIII, which is critical for blood clotting.

Other names: Factor VIII stimulant

Targets

BB-031 (Von Willebrand factor)

Beyond the preview

Go deeper on ADGN-F8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADGN-F8.

Explore the full profile